Where Will the AI Budget Actually Come From?
Explore how organizations can think differently about AI investment by redesigning existing workflows and reinvesting measurable productivity and value.
One question kept coming back across the conversations at Fierce Pharma Week 2026: where will the AI budget actually come from?
Every function wants AI — Commercial, Marketing, Medical, Field teams — while technology teams are being asked to build the infrastructure underneath all of it. Very few organizations have an unlimited new pool of money labeled "AI." The more useful question may not be where to find a new AI budget, but which existing spend AI can already perform differently.
Several existing pools of spend are natural candidates for this kind of self-funding transformation: agency and services spend on analytics, reporting, campaign operations, and content production; MarTech spend, as agents increasingly orchestrate capabilities across an already fragmented stack; media spend, where even modest improvements in targeting and sequencing create reinvestable value; field operations, where productivity gains create capacity for more meaningful HCP engagement rather than headcount reduction; content and MLR operations; and IT and data operations.
Industry estimates put meaningful value behind this: analysts have estimated tens of billions of dollars in annual generative AI value across pharma and medtech commercial functions, with productivity gains potentially equivalent to a significant share of marketing spend and measurable improvements in field-team effectiveness. The number worth caring about, though, isn't the estimate — it's the mechanism: baseline current spend, automate or augment the workflow, quantify the realized capacity or savings, and reinvest part of that value into scaling the next workflow.
That reframes the funding conversation from "can we afford this" to "which of our current cost centers is this actually already inside of." For CIOs, CTOs, CMOs, and CFOs, that's a conversation worth having jointly rather than function by function — because the alternative is every department funding its own AI point solution and recreating the exact fragmentation problem AI was supposed to solve.
This piece reflects broader discussion and analysis from Fierce Pharma Week 2026 on AI investment models in pharma commercial organizations.
